C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 254-262

  Matsumoto, Takayuki ^j,l   Hibi, Toshifumi ^a   Sakuraba, Atsushi ^a   Watanabe, Mamoru ^b   Motoya, Satoshi ^c   Ito, Hiroaki ^d   Sato, Noriko ^e   Yoshinari, Toru ^e   Motegi, Kenta ^f   Kinouchi, Yoshitaka ^g   Takazoe, Masakazu ^h   Suzuki, Yasuo ⁱ   Kawakami, Kazuhiko ^k   Hirata, Ichiro ^m   Tanaka, Shinji ⁿ   Ashida, Toshifumi ^o   Matsui, Toshiyuki ^p  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

^d Kinshukai Infusion Clinic   (Japan)

^e MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^f GUNMA PREFECTURAL CANCER CENTER   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Social Insurance Central General Hospital   (Japan)

ⁱ TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^j KYUSHU UNIVERSITY   (Japan)

^k Matsuda Hospital Colo Proctological Institute   (Japan)

^l HYOGO COLLEGE OF MEDICINE   (Japan)

^m FUJITA HEALTH UNIVERSITY   (Japan)

ⁿ HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^o ASAHIKAWA MEDICAL COLLEGE   (Japan)

^p Fukuoka University Chikushi Hospital   (Japan)

more..

Author keywords

C reactive protein; Crohn's disease; Crohn's disease activity index; Predicting loss of response; Serum infliximab trough level

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84896713030     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0807-0     Document Type: Article

References (22)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-97.
2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 1997;337:1029-35.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
4. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760-7.
5. Allez M, Karmiris K, Louis E, Assche GV, Ben-Horin S, Klein A, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-66.
6. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-72.
7. Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis. 2012;18:1480-7.
8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63.
9. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-54.
10. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-9.
11. Guerra I, Chaparro M, Bermejo F, Gisbert JP. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr Drug Metab. 2011;12:594-8.
12. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
13. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol. 1997;9:939-44.
14. Song L, Hanlon DW, Chang L, Provuncher GK, Kan CW, Campbell TG, et al. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease. J Immunol Methods. 2011;372:177-86.
15. Kato K, Fukunaga K, Kamikozuru K, Kashiwamura S, Hida N, Ohda Y, et al. Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease. Gut Liver. 2011;5:37-45.
16. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol. 1999;163:1521-8.
17. Knudsen LS, Ostergaard M, Baslund B, Narvestad E, Petersen J, Nielsen HJ, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol. 2006;35:489-91.
18. Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. Clin Exp Rheumatol. 2006;24:38-44.
19. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-31.
20. Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:421-7.
21. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568-76.
22. Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18:1647-54.